In addition, Xu et al. showed that miR-133b could alleviate glioma development via repressing the Wnt/β-catenin signaling pathway by inhibiting EZH2, which provides a potential treatment biomarker for glioma [48]. Here, EZH2 is linked to central nervous system cancer.